English
French
IntelGenx's robust and diversified product pipeline, leveraging the VersaFilm® and VetaFilmTM proprietary oral film platforms, addresses significant market opportunities and unmet patient needs
Differentiated Products
| Indication (Molecule) | Partner | Formulation Development |
Clinical | Filing | Launch | ||
|---|---|---|---|---|---|---|---|
 |
 |
Migraine - RIZAPORT® (Rizatriptan) |
   |
|
|||
|
Erectile Dysfunction - EXORDIA® (Tadalafil) |
 |
|
|
|||
|
Schizophrenia (Loxapine) |
Available |
|
|
|||
|
Neurodegenerative Brain Diseases (Montelukast) |
Available |
|
|
|||
|
Opioid Dependence (Buprenorphine / Naloxone) |
 |
|
|
|||
|
Chronic Pain (Buprenorphine) |
 |
|
|
|||
|
Treatment-Resistant Depression (N, N-Dimethyltryptamine) |
 |
|
|
|||
Animal Health
| Indication (Molecule) | Partner | Formulation Development |
Clinical | Filing | Launch | ||
|---|---|---|---|---|---|---|---|
 |
|
Undisclosed |  |
|
|
||
Cannabinoids
| Product | Partner | Formulation Development |
Clinical | Filing | Launch | ||
|---|---|---|---|---|---|---|---|
 |
|
CBD |  |
|
|||
|
THC | |
|
||||
|
THC:CBD | |
|
||||
Pipeline Disclaimer
The information included on this site reflects IntelGenx Corp. clinical development pipeline and is not intended for promotional purposes. It includes new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of August 25, 2020. IntelGenx assumes no duty to update this information.
For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.